Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Guess I was right and just wait until the 8k comes out. This is gonna really take off. Congrats to all. This is gonna be a 35 BO IMHO. I bought a lot more today and everyone should as well.
How can you prove that he is a crook? Just cause he hasn't made a deal or announced it yet?
Pre-Dance Jitters
Jun. 25, 2018 1:02 PM ET
Summary
Undervalued company at just a $115 million market cap with low float, strong insider and 10% institutional holders, Recent analyst coverage average 12 month target at $7, or a 100%+.
First product, Symjepi FDA approval announced June 2017.
Mylan Epipen shortages on top of last years pricing debacle tarnishing Epipen reputation.
Improved EPI PFSdesign includes smaller size which could lead to greater penetration in bothnon-retail and consumer markets.
Recent sell offunwarranted but provides opportunity for investors.
Intro
Adamis Pharmaceuticals (NASDAQ:ADMP) expects to announce a partner for their first product, a pre-filled syringe containing the drug Epinephrine. While this process has taken longer than expected the company assured Investors in May filing that they were close to closing a partnership deal for Symjepi. FDA approval of Symjepi Jr for children under 66 lbs is expected later in 2018.
Mylan continues to dominate this market with its Epipen product, which last year showed the market to be around 1.2 billion and growing. Unlike the simple syringe Adamis developed, Mylan’s Epipen is rather more complex. The design intended to hide needle from patients involves greater complexity, forcing costs higher.
Adamis intends to be the low-cost producer in every market they enter and the simpler design of Symjepi gives Adamis a pricing advantage over their competition. The form factor or physical size of Symjepi is also a competitive advantage as users prefer a smaller device as opposed to the bulkier Epipen.
Consumer groups over the last few years have not only objected to some of Mylan’s pricing but also pointed out the added complexity of the auto-injector introduces potentially life threatening reliability issues involving not only the mechanical design but the ability of the device to be properly used in an emergency. No such concerns surround a syringe.
Pipeline
The Adamis pipeline demonstrates Adamis is not a one-trick pony when it comes to potential products. Most of the markets Adamis is addressing going forward are considerably larger than the market for their first product, Symjepi & as can be seen by the chart taken from the Adamis webpage, most of these products are well along in development cycle and expected to go to market in the next 12 months.
It should be noted the FDA approved syringe used in the Symjepi product can be used for multiple products besides Epinephrine. APC-6000 for instance will be utilizing this syringe to deliver Naloxone, a long approved drug for use in combating Opioid overdose. The Naloxone market could be considerably larger than Symjepi.
It is reasonable to expect other such spin-off products based on this platform device ensuring Adamis as the low cost producer in each market they enter.
Adamis has also developed their own inhaler (APC-1000) as well as obtaining an advanced inhaler (APC-4000) designed originally by 3M Corp. The inhaler markets are really the crown jewels for Adamis and by far the largest potential markets for them.
GlaxoSmithKline generated over $786 million in global sales for 2016 with its Flovent® Diskus® product for asthma, delivering fluticasone. Fluticasone is a corticosteroid medicine commonly prescribed to prevent certain cells in the lungs and breathing passages from releasing substances which cause asthma symptoms. Adamis believes their APC-4000 product could successfully compete in this market utilising the Adamis (3M) Platform Inhaler to distribute fluticasone to the patient. With a lower price and a more effective inhaler design delivering quicker response times while using less drug for the same effectiveness should ensure Adamis is competitive in this large market.
Concerns
Symjepi was approved last June with a partnership expected almost immediately by most investors. While one can speculate why there currently is no partnership that’s not particularly relevant to evaluating Adamis today. In May Adamis confirmed they were engaged in partnership talks and expected to conclude those shortly.
Capital requirements suggest some sort of capital raise will be required in due course. This should hardly come as a surprise for a small cap, pre-revenue company in development of new products. However, there are also several scenarios in which this could be largely or wholly be avoided entirely.
Since we’re not presently privy to the terms of any upcoming partnership deal this is only speculation but serves to illustrate there can be multiple possible paths for the company to satisfy it’s capital needs without the need for additional dilution.
In the previous Allergan deal, Adamis received $10M upfront with another $10M milestone payment due upon FDA approval. Instead the FDA handed Adamis another CRL costing them both the partnership and another year to respond to the CRL. Should the next partnership deal be anything similar in terms this would forestall the need for immediate Capital.
There are still several warrants in effect that are callable by Adamis should the share price exceed different price points. This would require the stock price to rise significantly from its current levels & remain there for a period of time so this path is less likely but still possible.
Should any partnership result in rapid move into market the ensuing revenues could offset or reduce capital requirements. These are details we’re not likely to know even after an announcement.
Assuming a capital raise is required but occurs after a partnership announcement, the dilution would be substantially less due to expected rise in share price.
Conclusion
Adamis is well positioned to move forward on development of multiple products. Partnership for their first product Symjepi is expected soon & should have a major impact on share price as the company is currently priced for worst case scenario thanks to jitters from investors looking backwards rather than forwards.
It would seem reasonable to expect that any partnership deal could likely include multiple products still in development by Adamis. This would also explain why negotiations may have been more complex than they might have for a single product only.
With a depressed share price, a short position well over 3 million shares and a gap on the chart all the way back to $8 one could expect fireworks whenever a partnership is finally announced. Investors would do well to focus on the fundamentals of the company moving forward as the pipeline tells a compelling growth story and opportunity for investors.
Marley lockup period is over. Does anyone on the board think they are selling?
Does anyone think that Marley is selling?
New Jericho Man. I know some don't appreciate all your hard work you do for the board. I want to let you know we do. When is the lock up period over on Marley? And in your opinion? Do you think they will sell it off like Candace Crawford did?
New Jericho Man. You have the best insight IMO. What do you think the current state of the NBEV. I think we did around 16.5 Q4 based on the Roth Presentation and they will run them concurrent to 1st Q earnings. Which will be good based on what the CEO said on his blog.
Thanks in advance.
NEW JERICHO MAN....Do you think they registered them to sell them? Or did they have to register them? Thank u. I don't want to see what Crawford did with her shares happen.
Did everyone see 13G report that Marley register there shares? Joe or New Jerico. Can some explain this? Thanks
Joe, Got to see the your video. Great Work. I have a lot of the same feeling as that. I have had a talked to Brent several times I could be more excited than I am now. The ? is can Brent and team cont to excute? I with out of doubt think so and not even ?..Now as far as the makers NSDQ and EDGX I have no idea when there gonna be off the bid and ask. But I don't think it's gonna be along time. IF THERE WAS EVER A TIME TO BUY THIS STOCK IS NOW. AND HOLD IT. We own a lot lot of shares and haven't sold one share. We even bought at 6.70.. With that said we have avg down. 2018-2019 will be great years for the company. In closing. The "Fundamentals will always win. Have some patience. NBEV will be a big winner for all of us.
Yes I will and have a full summary. As far vid from Joe. It just plays dark. IDK why that is. I see it's 38 min long however I can't!! HELP
Thanks to all.
Joe,
Same result. Can you put it on youtube? My firm has tried every way possible.
Joe,
I can promise I don't have a problem on my end. Is there a way you can post it to youtube? I have a meeting with Brent this afternoon.
Joe,
I tried to see what your said on Periscope but the feed was just blank. I am sure what you said was very insightful for the board. When will the feed be able to be seen??
Joe, I agree. When do you think they'll being gone?
New Jericho. I just want to clarity that we are talking about only the Coco Lib folks or are we talking about Marley too? Also is could I call you for 5 min to run over somethings? I much appreciated your help to this board and others. Thank You. Also. What is your thoughts on Brent? Do you think after this is over he can execute?
New Jerico.
Based on the schedule. Do you think that the COCO Folks are close to done selling?
Thank you NEW JER. Much appreciated. So ? for you. Is that they Marley guys can't sell any per the report until March 2018?
Alan, I am down and down BIG BIG and I am just beside myself about the whole thing. This I can tell you and No I am not defending Brent in any way but if he hasn't learned that he can't do these deals with all these shares with only a six month lock up period. He is a lot dummer than I thought. It sucks. Trust me I know. I think we will a lot on Tuesday. What I mean by that is the shorts attacked this as well as the idiots COCO LIB folks. I mean to do what they did is just moronic. Makes no logic what so ever. The shorts attacked this because they felt like Brent had to raise capital. If we find out they don't the shorts will cover and be gone. As far as the selling goes. I expect that to continue for the short term. But it's not like the have an infant amount of shares. If the show growth on top line and bottom line FUNDAMENTALS will eventually take over and the buyout will not be as quick as we all thought but the raise back to 10 by next year is possible. I do think it does get bought out at some point. I am thinking around 2019-20 for a big number based on the Market Cap. No one including you me or Brent or anyone on the board thought that the COCO LIB idiots where gonna just sell this off like that. I wish you the best of luck and I am in the same boat as everyone else. We will have to see what Tuesday brings.
What I am asking NEW Jericho. Can you post the sec.gov links of the deals that Brent made to acquire Marley Coco the Water Folks and Xing tea.
New Jericho, Could you do this board a huge favor? It would really bring perspective to it all. Can you provide the 13F/Gs for us with all the deals that Brent did with the shares and when the lockup periods are over? That would be excellent and well appreciated. Thank you so very much
Good Points New Jericho Man. The problem is there no way to really know that marley is selling. Do you know when the lock period was up on marley?
I don't think that Marley is selling simple cause the owners of Marley are already super super rich? I think those guys are waiting for a buyout? Does that make more sense? I am not one to argue either. I am just trying to logical. The Coco folks had no money.
This stock is broken!
Will we see 1s Price?????????
Thank you. Great post. Do you have an opinion on PT by END OF YEAR?
Thanks NewJerichoMan.. Can you provide any reassurance. I hold 55k shares. I wan this to be a big success up I am down so much money casue I bought a lot of them shares at 6.80.
I am new to this board. Are we safe does everyone think? I am down big big money! Can someone please help me understand why this is getting crushed besides Coco selling it and shorts killing it because the believe they have no cash? Please HELP
GET IN AT THESE PRICES AND HOLD. NBEV is GONNA BE a BIG BIG WINNER!!!!!!!!!!!
BIG BIG Money Coming!! HOLD ON!!!! Buy NOW and HOLD.
What is the date for Q1 report? Tomorrow?
Cause if you do CALL HIM AND ASK HIM? I wanna see if these story's match?
I hear it all the time over and over...BTW thanks for the 70K. I will do it again this week. People are so full of it on her o wait until the news o wait until the financials o wait until tom is with with the president.
LET TELL YOU SOMETHING.....
Every 8k has been no NEWS to make this stock move
2nd Can't even pay the auditors
3rd All he has done AKA TOMMY BOY. Is RUIN THIS Stock over the last 7 months of signing convets loan causing huge volume and dilution
4 NO CEO in the world has time for 30 min calls with every shareholder
EVERYONE MUST SEE THIS.
703-981-5044 Call him and ask him. I wanna see if the story's match up
Doubt me now??? Yes I didn't think so!
Dilution at it's finest!
Dilution is not over. We will see.0004 next week!! Guaranteed
Tom said today an RS is on the table and the convert loans are beating the shit out the stock!!!
Just like I said from the start I said why do u keep doing them. He said looking for equity partner.
Yep. 70K in last two weeks. Must be a Moran
TOMMY MADOFF!! This is the biggest SCAM on OTC
DULITON AT IT'S FINEST
PEOPLE BETTER GET SMART. LOOK AT BUY VOLUME VS SALE VOLUME. AND THEN GO BACK AND LOOK AT FRIDAY.
TOTALLY DISASTER.